Navigation Links
Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Date:2/11/2013

WAYNE, N.J., Feb. 11, 2013 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for riociguat, an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH.

"Bayer is submitting an NDA for riociguat for the treatment of two distinct forms of pulmonary hypertension.  If approved, riociguat would be the first pharmacological treatment for CTEPH, and it would have the potential to add an important new treatment option to the armamentarium for PAH," said Pamela A. Cyrus , MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.  "The submission of riociguat is an important milestone in our cardio-pulmonary pipeline and is an example of Bayer's commitment to advancing treatment for hard to treat diseases."

The submission is supported by data from two global Phase III studies of riociguat CHEST-1 and PATENT-1.  Data from these two studies were presented in October 2012 at CHEST 2012, the annual meeting of the American College of Chest Physicians (ACCP).  Both Phase III studies on riociguat met their primary endpoint.

About CHEST
CHEST (Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trial) is a
Phase III trial to assess the efficacy and safety of oral riociguat in the treatment of patients with either inoperable CTEPH or CTEPH which has persisted or reoccurred after pulmonary endarterectomy (PEA). CHEST is a multi-center, multi-national program with active centers in 26 countries. The program includes a randomized, double-blinded, placebo-controlled trial phase (CHEST-1) and an open label extension trial phase (CHEST-2).

In the CHEST-1 study, 261 p
'/>"/>

SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bayer Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets Dual Action Formula due to Product Labeling Error
2. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
3. MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data
4. MediSapiens liefert neue Cloud-Computing-App zur Analyse und Visualisierung multidimensionaler Genomdaten an Bayer HealthCare Pharmaceuticals
5. MediSapiens sapprête à fournir à Bayer HealthCare Pharmaceuticals une nouvelle application informatique en nuage pour analyser et visualiser les données génomiques multidimensionnelles
6. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
7. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
8. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
9. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
10. Bayer Partnership Delivers Industry-First Dose Management Offering
11. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Health, Inc. (Nasdaq: GHDX ) today announced plans ... improving the quality of diagnosis, communication and support for millions ... genetic conditions.   The subsidiary is expected to be established by ... 2013.  The new venture will be led by Randy Scott, ...
... 2012 TeDan Surgical Innovations , industry leader ... Phantom Series MIS Anterior Hip Retractor System . ... adjustable surgical arms with attachable retractors, enabling surgeons to ... a surgical assistant. Dr. Lawrence Menendez ...
Cached Medicine Technology:Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4New Minimally Invasive Hip Retractor Revolutionizes Anterior Hip Replacement Procedures 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... July 12, 2014 For those who are ... can readily absorb the nutrients in food. The enzymes literally ... are small enough to be absorbed by human bodies. According ... lack of enzymes in regular food is the cause of ... that was started by Michelle DelPresto, a mother of 3 ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
(Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... ... customers with an advanced BlackBerry® smartphone paging solution. Onset METAMessage® enables Indiana Paging Network ... RIMM) via their current pager number and eliminate the need to carry two devices. ... (PRWEB) April ...
... the number of preventable patient injuries in California hospitals ... drop in malpractice claims against physicians, according to a ... Researchers studied both medical malpractice claims and adverse events ... that changes in the frequency of adverse events were ...
... Experimental treatment offers hope against cancer that returns after castration ... that a new hormone treatment could be a weapon for ... that,s resistant to surgical removal of the testicles. , ... new drug treatments have been completed, however. At this point, ...
... ... comprehensive and successful anti-obesity program, First Lady Michelle Obama’s “Let’s Move” campaign must ... , ... (Vocus) April 14, 2010 -- To be a truly comprehensive and successful ...
... , ... the impact of statins on the progression of multiple sclerosis found a lower incidence of ... disease as compared to a placebo. , ... (Vocus) April 14, 2010 -- A UCSF-led study examining the impact of statins ...
... unsavory-sounding name "corn smut" wields different weapons from its ... it infects. The discovery by Stanford researchers marks the ... pathogen. The finding upends conventional notions of how ... approaches to fighting disease not only in plants but ...
Cached Medicine News:Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 2Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 3Health News:Better patient safety linked to fewer medical malpractice claims in California 2Health News:Hormone Therapy May Fight Resistant Prostate Cancer 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 4Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 2Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 3Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 4Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 2Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 3Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 4
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Testing for Strabismus (ocular misalignment) just became easier. By simply placing the StrabismoScope over the patient's eye, the examiner is able to observe the occluded eye directly, but the patien...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Medicine Products: